173 related articles for article (PubMed ID: 18503584)
1. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma.
Nimmanapalli R; Gerbino E; Dalton WS; Gandhi V; Alsina M
Br J Haematol; 2008 Aug; 142(4):551-61. PubMed ID: 18503584
[TBL] [Abstract][Full Text] [Related]
2. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
3. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.
Damiano JS; Cress AE; Hazlehurst LA; Shtil AA; Dalton WS
Blood; 1999 Mar; 93(5):1658-67. PubMed ID: 10029595
[TBL] [Abstract][Full Text] [Related]
4. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.
Chen Q; Van der Sluis PC; Boulware D; Hazlehurst LA; Dalton WS
Blood; 2005 Jul; 106(2):698-705. PubMed ID: 15802532
[TBL] [Abstract][Full Text] [Related]
5. Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.
Zheng Y; Wang Q; Li T; Qian J; Lu Y; Li Y; Bi E; Reu F; Qin Y; Drazba J; Hsi E; Yang J; Cai Z; Yi Q
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381622
[TBL] [Abstract][Full Text] [Related]
6. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
7. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
Neri P; Ren L; Azab AK; Brentnall M; Gratton K; Klimowicz AC; Lin C; Duggan P; Tassone P; Mansoor A; Stewart DA; Boise LH; Ghobrial IM; Bahlis NJ
Blood; 2011 Jun; 117(23):6202-13. PubMed ID: 21474670
[TBL] [Abstract][Full Text] [Related]
8. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
Xiang Y; Remily-Wood ER; Oliveira V; Yarde D; He L; Cheng JQ; Mathews L; Boucher K; Cubitt C; Perez L; Gauthier TJ; Eschrich SA; Shain KH; Dalton WS; Hazlehurst L; Koomen JM
Mol Cell Proteomics; 2011 Nov; 10(11):M110.005520. PubMed ID: 21846842
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells.
Gazitt Y; Fey V; Thomas C; Alvarez R
Int J Oncol; 1998 Aug; 13(2):397-405. PubMed ID: 9664139
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.
Harada N; Nagasaki A; Hata H; Matsuzaki H; Matsuno F; Mitsuya H
Acta Haematol; 2000; 103(3):144-51. PubMed ID: 10940652
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells.
Efferth T; Fabry U; Osieka R
Anticancer Res; 2002; 22(1A):231-4. PubMed ID: 12017294
[TBL] [Abstract][Full Text] [Related]
12. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
[TBL] [Abstract][Full Text] [Related]
13. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.
Hayun M; Saida H; Albeck M; Peled A; Haran-Ghera N; Sredni B
Exp Hematol; 2009 May; 37(5):593-603. PubMed ID: 19375650
[TBL] [Abstract][Full Text] [Related]
14. Alkylating agents induce activation of NFkappaB in multiple myeloma cells.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Leuk Res; 2008 Jul; 32(7):1144-7. PubMed ID: 18083229
[TBL] [Abstract][Full Text] [Related]
15. Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells.
Zub KA; Sousa MM; Sarno A; Sharma A; Demirovic A; Rao S; Young C; Aas PA; Ericsson I; Sundan A; Jensen ON; Slupphaug G
PLoS One; 2015; 10(3):e0119857. PubMed ID: 25769101
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan.
Hu Y; Kirito K; Yoshida K; Mitsumori T; Nakajima K; Nozaki Y; Hamanaka S; Nagashima T; Kunitama M; Sakoe K; Komatsu N
Mol Cancer Ther; 2009 Aug; 8(8):2329-38. PubMed ID: 19671732
[TBL] [Abstract][Full Text] [Related]
17. Cell adhesion to fibronectin down-regulates the expression of Spy1 and contributes to drug resistance in multiple myeloma cells.
Fei M; Hang Q; Hou S; Ruan C
Int J Hematol; 2013 Oct; 98(4):446-55. PubMed ID: 24037419
[TBL] [Abstract][Full Text] [Related]
18. Proteometabolomics of Melphalan Resistance in Multiple Myeloma.
Koomen DC; Guingab-Cagmat JD; Oliveira PS; Fang B; Liu M; Welsh EA; Meads MB; Nguyen T; Meke L; Eschrich SA; Shain KH; Garrett TJ; Koomen JM
Methods Mol Biol; 2019; 1996():273-296. PubMed ID: 31127562
[TBL] [Abstract][Full Text] [Related]
19. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.
Hunsucker SA; Magarotto V; Kuhn DJ; Kornblau SM; Wang M; Weber DM; Thomas SK; Shah JJ; Voorhees PM; Xie H; Cornfeld M; Nemeth JA; Orlowski RZ
Br J Haematol; 2011 Mar; 152(5):579-92. PubMed ID: 21241278
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma.
Bailey CK; Budina-Kolomets A; Murphy ME; Nefedova Y
Cancer Biol Ther; 2015; 16(9):1422-6. PubMed ID: 26176532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
